ENTYVIO 108 mg, solution injectable en seringue préremplie

( ARTG ) Ulcerative colitis,Treatment of adult patients with moderate to severe ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF-alpha) antagonist.​​​‍​​‍​​​​‍​​‍‍,Crohns disease,Treatment of adult patients with moderate to severe Crohns disease who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF-alpha) antagonist.,Pouchitis,Entyvio is indicated for the treatment of adult patients with moderate to severe chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.